STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,599,178)	$ (5,201,779)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,064,231	316,083
Share-based payments for services	347,227	511,424
Equity based compensation	3,581,204	1,104,490
Common stock contributed to 401(k) plan	79,896	72,124
Shares issued for settlement of clinical research costs	0	1,290,000
Loss (gain) on derivative instruments	2,282,518	(4,589,135)
Capitalized lease interest	0	64,432
(Increase)/decrease in assets:
Receivables	476	(4,579)
Prepaid expenses	96,951	(74,741)
Supplies used for R&D and manufacturing	(67,185)	(115,774)
Increase/(decrease) in liabilities:
Accounts payable	(765,872)	(1,489,234)
Accrued expenses	20,110	82,580
Due to employees	(34,034)	245,074
Other liabilities	3,438	(1,057)
Net cash used in operating activities	(7,990,218)	(7,790,092)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(752,797)	(160,920)
Expenditures for patent costs	(13,996)	(67,661)
Net cash used in investing activities	(766,793)	(228,581)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	12,917,632	0
Payments of stock issuance costs	(190,553)	(80,224)
Proceeds from the purchase of stock by officers and directors	184,990	0
Proceeds from exercise of warrants	2,069,272	3,305,387
Proceeds from exercises of options	49,898	0
Payments on obligations under finance lease	(389,132)	(2,521)
Net cash provided by financing activities	14,642,107	3,222,642
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	5,885,096	(4,796,031)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	8,444,774	10,310,044
CASH AND CASH EQUIVALENTS, END OF PERIOD	14,329,870	5,514,013
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in current liabilities	318,984	0
Capitalizable patent costs included in current liabilities	13,465	0
Right of use asset acquired and liability incurred	13,712	0
Finance lease obligation included in accounts payable	983	428
Prepaid consulting services paid with issuance of common stock	137,244	83,415
Accrued consulting services to be paid with common stock	165,000	0
Fair value of warrant liabilities on date of exercise	2,546,535	0
Stock issuance costs included in current liabilities	116,549	10,000
Cash paid for interest	$ 585,748	$ 902,091